Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis
The results provide a greater understanding of mepolizumab's effectiveness, demonstrating a substantial improvement in asthma outcomes, irrespective of baseline BEC and the presence of comorbid CRSwNP.
Authors
- Inés Palomares
- Thomas Paulsson
- Florence Schleich (ORCID: https://orcid.org/0000-0002-2678-1373)
- Claudio Micheletto (ORCID: https://orcid.org/0000-0002-1138-3882)
- Stelios Loukides (ORCID: https://orcid.org/0000-0002-4278-9922)
- Jyothi U. Menon (ORCID: https://orcid.org/0000-0002-0762-3513)
- Jörg D. Leuppi (ORCID: https://orcid.org/0000-0002-5554-0675)
- Florent Guelfucci (ORCID: https://orcid.org/0000-0002-0586-6589)
- Nathan Gaw (ORCID: https://orcid.org/0000-0001-7879-8946)
- Rekha Chaudhuri (ORCID: https://orcid.org/0000-0001-8007-949X)
- Enrico Marco Heffler (ORCID: https://orcid.org/0000-0002-0492-5663)
- Armel Ngami
- Carla Y. Vossen
- Cristian Domingo
- Konstantina Kallinikou
Institutions
- University of Verona (IT)
- Universitat Autònoma de Barcelona (ES)
- Humanitas University (IT)
- University of Liège (BE)
- University of Basel (CH)
- National and Kapodistrian University of Athens (GR)
- Corporació Sanitària Parc Taulí (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- GlaxoSmithKline (Spain) (ES)
- Physiol (Belgium) (BE)
- IRCCS Humanitas Research Hospital (IT)
- University of Glasgow (GB)
Publication Details
- Journal
- Allergy
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1111/all.16618
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Celltrion Healthcare
- Celltrion